Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort …
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
G Corcoran, A Karunakara, B Vaughn…
Movement …, 2021
ovid.com
… previously known as OXB-102, uses a … clinically relevant effect. Further evaluation of ALPD is planned using a higher dose/volume open label cohort followed by a sham-controlled study…

